Geneva, March 20 -- International Clinical Trials Registry received information related to the study (ISRCTN17931168) titled 'Impact of Symprove in Ehlers-Danlos Syndrome' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: N/A: single arm study
Masking: Open (masking not used)
Control: Uncontrolled
Assignment: Single
Purpose: Supportive care
Primary Sponsor: Symprove Ltd
Condition:
Ehlers-Danlos syndromes
Genetic Diseases
Intervention:
All participants will receive a 12-week course of Symprove (70 ml per day), a water-based solution that contains billions of live and active bacteria. The water-based formula makes sure that the bacteria are alive, active and ready to help stimulate the good bacteria already in the gu...